PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #ADEPT–BMS Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #ADEPT–BMS Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease